AstraNu Raises $3.5 Million For Chip-Scale Medical Imaging Engine

AstraNu has raised $3.5 million in seed funding to commercialize a chip-scale optical coherence tomography imaging engine for medical-device manufacturers.

Celesta Capital led the round, with co-investment from the New Jersey Innovation Evergreen Fund, a program administered by the New Jersey Economic Development Authority.

AstraNu will use the funding to expand its photonics development team, validate the imaging engine with commercial partners, and prepare the technology for volume manufacturing.

Commercializing Nokia Bell Labs Technology

AstraNu spun out of Nokia Bell Labs in May 2025 with backing from Celesta.

The company was the first venture created through a collaboration between Celesta and Nokia to commercialize technologies developed at Bell Labs.

AstraNu has since demonstrated swept-source optical coherence tomography performance at chip scale and is preparing to place the technology in partner test environments.

Optical coherence tomography uses light to generate detailed images of tissue. The technology is widely associated with ophthalmology but can also support applications in ear, nose, and throat care, urology, oncology, and other fields.

Swept-source OCT can provide faster and deeper imaging than older spectral-domain systems, but the cost and physical size of conventional equipment have limited adoption in some products.

Reducing The Size And Cost Of Swept-Source OCT

AstraNu says its module is more than 10 times smaller than conventional swept-source systems while targeting price levels associated with spectral-domain OCT.

Rather than building complete medical devices, the company plans to supply the imaging engine to established device, optics, and imaging companies. Those partners can integrate the module into their own products and clinical applications.

Ophthalmology is AstraNu’s initial commercial market because it already represents the largest established use of OCT.

The company is also working with developers evaluating applications in other medical specialties.

The seed capital will help AstraNu move from laboratory development toward manufacturing readiness and customer validation. This process will require the company to demonstrate consistent performance, manufacturability, reliability, and suitability for integration into regulated medical products.

KEY QUOTES:

This funding enables us to drive our strategy forward by building out our photonics development team and manufacturing readiness ahead of customer volume. Celesta’s backing, together with the NJIEF’s support, gives us the runway to get our engine into partner testbeds and validate the performance we have achieved.

Kevin Blalock, President and General Manager of AstraNu

AstraNu is an outstanding example of where we invest: foundational technology from one of the world’s leading research labs, with the potential to change what is possible in a large and established market. By delivering a new cost and performance package, AstraNu is opening this imaging technology to entirely new applications and markets. Scaling a technology like this from the lab into volume production requires disciplined operations and commercial partners – supporting founders in this work is what we do. Celesta is delighted to lead this round alongside NJEDA, and to continue our partnership with Nokia to build globally competitive companies around market-shifting technologies.

Matthew Marsh, Managing Partner and CFO of Celesta Capital